Alpha7 Integrin-Mediated Hypertrophic Signaling and Growth in Skeletal Muscle

Alpha7 整合素介导的骨骼肌肥大信号传导和生长

基本信息

项目摘要

DESCRIPTION (provided by applicant): It is estimated that 19% of the population in the US will be older than 65 years by 2030. The majority of these individuals will lose mobility and succumb to disability as a result of sarcopenia, or the decline in muscle mass and function that occurs with age. Current treatment for sarcopenia includes growth hormone and androgenic compounds that inconsistently ameliorate muscle loss. The long-term goal of our laboratory is to develop novel and effective interventions that can counteract muscle loss with aging. The specific objective of this proposal is determine the extent to which the α7 integrin is an intrinsi modulator of load-induced skeletal muscle growth and assess whether restoration of α7 integrin protein can prevent anabolic resistance to mechanical loading in aged skeletal muscle. The α7 integrin is a transmembrane adhesion protein that can link the actin cytoskeleton inside muscle fibers to the extracellular matrix (ECM), specifically laminin. Our recently published studies have clearly demonstrated that transgenic overexpression of the α7 integrin can enhance new fiber synthesis and growth in young muscle following eccentric exercise. To our knowledge, no studies have been conducted to determine whether the α7 integrin is an intrinsic modulator of load-induced muscle growth or the extent to which α7 integrin function is decreased with age, providing the underlying basis for anabolic resistance to mechanical loading. Our central hypothesis is that the α7 integrin is an essential mechanotransducer in skeletal muscle and that restoration of integrin expression can overcome anabolic resistance to mechanical loading with age. Thus, this work seeks to 1) determine the extent to which the α7 integrin is an intrinsic regulator of load- induced hypertrophic signaling and growth in skeletal muscle, and 2) determine the extent to which loss of α7 integrin protein expression is the basis for anabolic resistance to mechanical loading in aged skeletal muscle. This work is highly innovative because it is the first to evaluate the α7 integrin as an underlying basis of muscle atrophy with age and incorporates a novel strategy for countering anabolic resistance. The proposed work is significant because it is expected to establish the α7 integrin as a potential therapeutic target fr the stimulation of muscle growth in an aged microenvironment. Ultimately, such knowledge has the potential to initiate a continuum of research that will prevent and treat sarcopenia.
描述(由适用提供):据估计,到2030年,美国有19%的人口将超过65岁。这些人中的大多数将因肌肉减少症而失去流动性并屈服于残疾,或者随着年龄的增长而发生的肌肉质量和功能下降。目前对肌肉减少症的治疗包括生长本质和雄激素化合物,可不一致地改善肌肉损失。我们实验室的长期目标该提案的具体目标确定了α7整合素是负载诱导的骨骼肌生长的内ininsi调节剂,并评估α7整合蛋白蛋白的恢复是否可以防止年龄骨骼肌的机械载荷抗性。 The α7 integrin is a transmembrane adhesive protein that can link the actin cytoskeleton inside muscle fibers To our knowledge, no studies have been conducted to determine whether the α7 integrin is an intrinsic modulator of load-induced muscle growth or the extent to which α7 integrin function is decreased with age, providing the underlying basis for anabolic resistance to mechanical loading.我们的中心假设是α7整联蛋白是骨骼肌中必不可少的机械转换蛋白,而整联蛋白表达的恢复可以克服随着年龄的增长的机械载荷的抗性。这是该工作的目的1)确定α7整合素是负荷诱导的肥厚信号传导和骨骼肌生长的内在调节剂,以及2)确定α7整合蛋白蛋白表达的损失的程度是对年龄骨骼骨骼肌肉中机械载荷的合成代谢载荷的基础。这项工作具有很高的创新性,因为它是第一个评估α7整合蛋白作为肌肉萎缩的基础,并纳入了应对合成代谢抗性的新策略。提出的工作很重要,因为预计它将建立α7整合素作为潜在的治疗靶点,从而刺激老化的微环境的肌肉生长。最终,这种知识有可能发起一大批研究,以预防和治疗肌肉减少症。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Marni D. Boppart其他文献

Marni D. Boppart的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Marni D. Boppart', 18)}}的其他基金

Development of a Cell-Based Therapy to Improve Recovery Following Immobilization
开发基于细胞的疗法以改善固定后的恢复
  • 批准号:
    10200674
  • 财政年份:
    2018
  • 资助金额:
    $ 16.8万
  • 项目类别:
Development of a Cell-Based Therapy to Improve Recovery Following Immobilization
开发基于细胞的疗法以改善固定后的恢复
  • 批准号:
    9762840
  • 财政年份:
    2018
  • 资助金额:
    $ 16.8万
  • 项目类别:
Development of a Cell-Based Therapy to Improve Recovery Following Immobilization
开发基于细胞的疗法以改善固定后的恢复
  • 批准号:
    10445294
  • 财政年份:
    2018
  • 资助金额:
    $ 16.8万
  • 项目类别:

相似国自然基金

促细胞外囊泡分泌的绒毛膜纳米纤维仿生培养体系的构建及其在宫腔粘连修复中的应用研究
  • 批准号:
    32301204
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
载Pexidartinib的纳米纤维膜通过阻断CSF-1/CSF-1R通路抑制巨噬细胞活性预防心脏术后粘连的研究
  • 批准号:
    82370515
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目
泛素连接酶SMURF2通过SMAD6-COL5A2轴调控宫腔粘连纤维化的分子机制研究
  • 批准号:
    82360301
  • 批准年份:
    2023
  • 资助金额:
    31 万元
  • 项目类别:
    地区科学基金项目
负载羟基喜树碱的双层静电纺纳米纤维膜抑制肌腱粘连组织增生的作用和相关机制研究
  • 批准号:
    82302691
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
活血通腑方调控NETs干预术后腹腔粘连组织纤维化新途径研究
  • 批准号:
    82374466
  • 批准年份:
    2023
  • 资助金额:
    48 万元
  • 项目类别:
    面上项目

相似海外基金

The role of LTBP2 in glaucoma
LTBP2在青光眼中的作用
  • 批准号:
    10608873
  • 财政年份:
    2023
  • 资助金额:
    $ 16.8万
  • 项目类别:
Dissecting the Mechanims of Platelet-Fibrin interaction
剖析血小板-纤维蛋白相互作用的机制
  • 批准号:
    10722537
  • 财政年份:
    2023
  • 资助金额:
    $ 16.8万
  • 项目类别:
Mechanisms of microtubule-mediated cranial neural crest EMT and differentiation
微管介导的颅神经嵴EMT和分化机制
  • 批准号:
    10507726
  • 财政年份:
    2022
  • 资助金额:
    $ 16.8万
  • 项目类别:
Generation and Characterization of Novel Large Animal Models of Usher Syndrome Type 3
3 型亚瑟综合症新型大型动物模型的生成和表征
  • 批准号:
    10706969
  • 财政年份:
    2022
  • 资助金额:
    $ 16.8万
  • 项目类别:
New Therapeutic Leads for Proteinuric Kidney Diseases
蛋白尿性肾病的新治疗方法
  • 批准号:
    10673944
  • 财政年份:
    2022
  • 资助金额:
    $ 16.8万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了